FibroGen (NASDAQ:FGEN) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of FibroGen (NASDAQ:FGEN) in a research report issued on Wednesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Other research analysts have also recently issued reports about the stock. HC Wainwright raised shares of FibroGen to a “strong-buy” rating in a research note on Tuesday, December 17th. William Blair reissued a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th.

FibroGen Stock Down 2.6 %

Shares of FGEN stock opened at $0.46 on Wednesday. The firm has a 50 day moving average price of $0.48 and a two-hundred day moving average price of $0.46. The company has a market capitalization of $46.68 million, a PE ratio of -0.38 and a beta of 0.75. FibroGen has a 12-month low of $0.18 and a 12-month high of $2.93.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.21. The business had revenue of $46.33 million during the quarter, compared to analyst estimates of $34.00 million. During the same quarter in the previous year, the firm posted ($0.52) earnings per share. As a group, research analysts expect that FibroGen will post -0.8 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in FGEN. JPMorgan Chase & Co. grew its stake in shares of FibroGen by 430.7% during the third quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock worth $668,000 after buying an additional 1,358,194 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of FibroGen by 139.6% during the second quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock worth $1,179,000 after buying an additional 769,586 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of FibroGen by 3.1% during the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after buying an additional 32,884 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of FibroGen during the third quarter worth $307,000. Finally, FMR LLC grew its stake in shares of FibroGen by 21.8% during the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 68,569 shares during the last quarter. 72.71% of the stock is owned by institutional investors.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.